HBT1 (YDL233C)

• 1 gram powder
• 30 mL liquid solution (commonly listed at 20 mg per mL, 600 mg total)

Research suggests HBT1 may

• Act as a positive allosteric modulator of the AMPA receptor
• Bind the ligand binding domain of AMPA receptors in a glutamate dependent manner
• Enhance AMPA mediated synaptic transmission without acting as a strong direct agonist
• Influence activity dependent neuroplasticity signaling, including BDNF related outcomes in neuronal models
• Support long term potentiation style mechanisms in learning and memory research contexts

HBT1 is commonly explored in research models involving

• Cognitive performance and memory formation
• Synaptic plasticity and learning pathways
• Neurotrophic signaling and BDNF modulation
• Neuropsychiatric research where glutamate signaling is implicated
• Neurodegeneration adjacent models where plasticity support is being studied
• Fatigue, motivation, and task engagement models where excitatory tone is a variable

Because AMPA potentiation increases excitatory signaling, researchers commonly monitor for

• Overstimulation signals (restlessness, agitation like behavior in animal models)
• Sleep disruption like signals in wakefulness models
• Headache like proxies and increased sensitivity to stimulants when combined with other excitatory agents
• Seizure threshold concerns in high dose or sensitized models (a class level consideration for AMPA potentiation research)

Researchers often group HBT1 with stacks based on study intent: Glutamate and plasticity focused models: Cholinergic support models: Caution combinations

• Racetams (Piracetam, Aniracetam, Oxiracetam), Noopept, Coluracetam
• TAK 653, other AMPA modulation tools (avoid redundant overlap in the same model)
• Alpha GPC, CDP Choline, acetylcholine pathway tools (commonly paired in cognition studies)
• Multiple strong excitatory agents together (ampakines plus high stimulant load, or multiple AMPA potentiators) due to overstimulation and seizure threshold considerations in sensitive models